QUEST Global will focus on a more detailed assessment of health economic outcomes, including the potential for medicinal cannabis to reduce the number of medications a patient requires and their need for healthcare services.

Australians living with one of 200 chronic conditions may now be eligible to participate in what is expected to become the world's largest study into the impact of medicinal cannabis treatment on health economic outcomes and quality of life for patients suffering from chronic health conditions.

The QUEST Global study, led by Curtin University and sponsored by ASX-listed medicinal cannabis supplier Little Green Pharma, will assess whether medicinal cannabis reduces the economic impact of chronic disease, by reducing both the number of medications a patient requires and their need for healthcare services.

"The increased focus on health economics in QUEST Global will mean ongoing costs will be analysed and provide a framework for thinking about how Australia should allocate its limited health resources to meet people's demands and needs for health care services, health promotion and prevention."

HIF CEO Justin James said the not-for-profit health insurer had enjoyed a partnership with Little Green Pharma since 2020 and was proud to continue supporting studies into the health benefits of medicinal cannabis.

no comments (yet)

sorted by: hot top controversial new old

there doesn't seem to be anything here